Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Medical Interventions in the Management of Mild Autonomous Cortisol Secretion (MACS)

  • By

  • Ee Wen Loh

  • Miguel Debono

  • June 30, 2026

Share

  • 1

    Mild autonomous cortisol secretion (MACS) is characterized by elevated cortisol levels without overt Cushing’s syndrome symptoms.

  • 2

    Surgical intervention, such as adrenalectomy, may improve metabolic outcomes in MACS patients with multiple comorbidities.

  • 3

    Metyrapone has shown promise in lowering nocturnal cortisol levels and improving metabolic risk parameters in MACS patients.

  • 4

    Mifepristone treatment has led to significant reductions in insulin resistance and HbA1c levels in patients with MACS.

  • 5

    Evidence for the efficacy of medical therapies in MACS remains inconsistent, highlighting the need for further research.

Original Source(s)

Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment

  • by Ee Wen Loh, Miguel Debono

  • June 30, 2026

Related Content

Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP

Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process